Requiring the State Workers' Compensation Commission to regulate fees and other charges for the reimbursements of prescription drugs and pharmaceutical services under certain circumstances; limiting covered reimbursements to a cost index or indexes; and requiring the Maryland Prescription Drug Affordability Board to conduct a study on prescription drug affordability challenges related to workers' compensation claims and report its findings and recommendations to certain committees of the General Assembly by March 1, 2026.